Evidence map›Paper›PMID 33537073›Full record

ReviewTheranostics2021

Ferroptosis as a novel therapeutic target for cardiovascular disease.

Xiaoguang Wu, Yi Li, Shuchen Zhang, Xiang Zhou

Open access · goldAbstract readReview
In one paragraph

Review in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 349 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
349citing papers in PubMed, 2 pooled it
65.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

349 citing papers in PubMed, 2 syntheses or guidelines pooled it, 613 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Ferroptosis as a target mechanism in heart and kidney disease.The Journal of clinical investigation · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Nutrients · 2026
    Article
  18. MLK3 promotes atherosclerosis by regulating ferroptosis in macrophages.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  19. Review
  20. Article

289 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xiaoguang WuDepartment of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Yi LiDepartment of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Shuchen ZhangDepartment of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Xiang ZhouDepartment of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Second Affiliated Hospital of Soochow University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell death is an important component of the pathophysiology of cardiovascular disease. An understanding of how cardiomyocytes die, and why regeneration of cells in the heart is limited, is a critical area of study. Ferroptosis is a form of regulated cell death that is characterized by iron overload, leading to accumulation of lethal levels of lipid hydroperoxides. The metabolism of iron, lipids, amino acids and glutathione tightly controls the initiation and execution of ferroptosis. Emerging evidence shows that ferroptosis is closely associated with the occurrence and progression of various diseases. In recent years, ferroptosis has been found to play critical roles in cardiomyopathy, myocardial infarction, ischemia/reperfusion injury, and heart failure. This article reviews the mechanisms by which ferroptosis is initiated and controlled and discusses ferroptosis as a novel therapeutic target for various cardiovascular diseases.

Indexed as

AnimalsCardiomyopathiesCardiovascular DiseasesCell DeathFerroptosisGlutathioneHumansIronLipid PeroxidationLipid PeroxidesMyocardial InfarctionMyocardial Reperfusion InjuryMyocytes, CardiacReactive Oxygen SpeciesGlutathioneIronLipid PeroxidesReactive Oxygen Speciescardiomyopathyferroptosisheart failureischemia/reperfusion injurymyocardial infarction

Identifiers

PMID33537073
PMCPMC7847684
OpenAlexW3120670495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.